Premium
Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?
Author(s) -
Mathias Carolina,
Zambalde Erika P.,
Rask Philip,
Gradia Daniela F.,
de Oliveira Jaqueline C.
Publication year - 2019
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/cge.13502
Subject(s) - breast cancer , biology , long non coding rna , disease , rna , genetics , computational biology , microrna , differential diagnosis , cancer , gene , bioinformatics , cancer research , medicine , pathology
Breast Cancer (BC) is the most commonly diagnosed cancer and is the leading cause of cancer deaths in women. BC is a heterogeneous disease with different clinical and genetic features. According to immunohistochemical markers, BC is subdivided into four main subtypes: luminal A, luminal B, ERBB2 positive and triple negative. Long non‐coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides and deregulated lncRNAs are associated with human diseases, including BC. In order to improve BC molecular classification, non‐coding RNAs (ncRNAs), including lncRNAs, have been used. In this review, we focus on lncRNAs with differential expression in BC subtypes and how these RNAs may act to contribute to BC heterogeneity. We also emphasize the potential of these lncRNAs as biomarkers.